Advertisement
| biologic therapies for severe asthma: Severe Asthma Kian Fan Chung, Elliot Israel, Peter G. Gibson, 2019-06-01 Severe asthma is a form of asthma that responds poorly to currently available medication, and its patients represent those with greatest unmet needs. In the last 10 years, substantial progress has been made in terms of understanding some of the mechanisms that drive severe asthma; there have also been concomitant advances in the recognition of specific molecular phenotypes. This ERS Monograph covers all aspects of severe asthma – epidemiology, diagnosis, mechanisms, treatment and management – but has a particular focus on recent understanding of mechanistic heterogeneity based on an analytic approach using various ‘omics platforms applied to clinically well-defined asthma cohorts. How these advances have led to improved management targets is also emphasised. This book brings together the clinical and scientific expertise of those from around the world who are collaborating to solve the problem of severe asthma. |
| biologic therapies for severe asthma: Respiratory Disease in Pregnancy Stephen E. Lapinsky, Lauren A. Plante, 2020-04-09 Covers a broad spectrum of respiratory diseases during pregnancy, in order to improve successful management of both mother and fetus. |
| biologic therapies for severe asthma: Severe Asthma in Children and Adolescents Erick Forno, Sejal Saglani, 2019-11-13 This book provides readers with a comprehensive review of severe asthma in children and adolescents, covering epidemiology, genetics, risk factors, co-morbidities, clinical presentation, diagnosis and treatment. Written by leaders in the field, chapter discussions draw on the mechanisms driving the disease, genetics, multidisciplinary approaches, immunomodulators, and other important aspects in the management of the disease. Severe Asthma in Children and Adolescents: Mechanisms and Management is designed to be a practical guide, opening with an introduction on the epidemiology of severe childhood asthma, as well as a discussion of special considerations of the disease unique to the preschool-aged patient. The distinctions between the diagnosis and management of asthma in young children of various ages, and specific approaches for the adolescent with severe asthma, including the transition into adult care are then addressed. Finally, the book closes with a discussion on the current state and future avenues for severe asthma research. Severe Asthma in Children and Adolescents is an indispensable reference for the healthcare professional, for basic and translational researchers, as well as for students, residents and fellows. |
| biologic therapies for severe asthma: Severe Asthma S. J. Szefler, Donald Y. M. Leung, 1996 Bridging the gap between basic science and clinical research, this comprehensive and fully up-to-date reference presents new directions in asthma care - examining the pathophysiology, epidemiology, immunology, environmental control, and psychosocial impact of severe asthma. |
| biologic therapies for severe asthma: Safe and Effective Medicines for Children Institute of Medicine, Board on Health Sciences Policy, Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), 2012-10-13 The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children. |
| biologic therapies for severe asthma: Advances in Asthma Akihito Yokoyama, 2018-12-18 This book provides discussions on bronchial asthma from a clinical perspective, focusing on the recent studies on its pathophysiology, diagnosis and treatment. It also explores the lastest findings regarding the phenotypes and endotypes of asthmatic patients, making it of particular interest to those involved with non-eosinophilic asthma and eosinophilic asthma. Further, it discusses the importance of ILC 2 in eosinophilic asthma, and the accumulated results from the forced oscilliation technique and periostin that are actively practiced in Japan. As some aspects of diagnosis and treatment are different in Western and Asian countries, it is important that the data is disseminated around the globe. The clinical questions addressed by the authors are critical and thought provoking, while the questions raised by the editors are instructive, informative and provide new perspectives on unresolved issues. This book appeals to wide readership from beginning learners to physicians in clinical practice and scholars engaging in basic research. |
| biologic therapies for severe asthma: Chronic Rhinosinusitis Wytske J. Fokkens, 2009 This issue will focus on treatments for Chronic Rhinosinusitis. Dr. Wyste Fokkens guest edits topics such as: Inflammatory mechanisms in chronic rhinosinusitis with or without nasal polyposis, European versus Asian Chronic rhinosinusitis. What did it teach us and what do we want to know, Epithelium, cilia and mucus, their importance in chronic rhinosinusitis Noam Cohen Noam, Aspirin intolerance: does desensitization alter the course of the disease, Anti-inflammatory effects of macrolides: applications in CRS, and more! |
| biologic therapies for severe asthma: Difficult To Treat Asthma Sandhya Khurana, Fernando Holguin, 2019-08-29 This book provides a practical, stepwise, evidence-based approach to effective management of patients with difficult to treat asthma. The impact of asthma on morbidity and healthcare utilization increases exponentially with severity. Severe refractory asthma accounts for less than 5% of all asthma. Its prevalence, however, is often overestimated as there are several other confounding factors that make asthma ‘difficult to treat’. Many novel (albeit expensive) therapies are now available and providers caring for patients with severe asthma are charged with selecting the best evidence treatment. This calls for complex and nuanced decision-making. Whether people with asthma gain and maintain control over their condition depends not only on the availability of effective drugs, but also multiple patient and healthcare provider behaviors. Therefore, now more than ever, it has become increasingly important to differentiate “difficult” from “severe refractory” asthma to allow identification of patients most likely to benefit from these therapies. This volume delves into the current understanding of mechanisms and increasingly recognized heterogeneity of this complex disease. It discusses a structured approach to identification and optimization of factors contributing to poor asthma control, including nonadherence, comorbidities and occupational/environmental triggers. The book includes ‘state of the art’ reviews on recent advances in traditional and targeted asthma therapies, as well as a glimpse into what the future may hold. Highlights include a comprehensive guide to management of severe asthma in children and pregnancy, as well as practical considerations to management of asthma based on different clinical phenotypes. Each chapter is authored by leading experts in the field who share their own clinical approach. This is an ideal guide for clinical pulmonologists and allergist/immunologists, as well as primary care providers, physician extenders in specialty practice, physicians in pulmonary/allergy training, and even industry partners. |
| biologic therapies for severe asthma: 2019 Pocket Guide for Asthma Management Global Initiative For Asthma, 2019-04-10 The Global Strategy for Asthma Management and Prevention provides a comprehensive and integrated approach to asthma management that can be adapted for local conditions and for individual patients. It focuses not only on the existing strong evidence base, but also on clarity of language and on providing tools for feasible implementation in clinical practice. The report is updated each year. The 2019 GINA report includes important new recommendations for treatment of mild asthma (page 16) and severe asthma (page 24). |
| biologic therapies for severe asthma: Immune Mediated Diseases Michael R Shurin, Yuri S. Smolkin, 2007-09-23 This volume includes contributions from the speakers of the Second IMD Congress (September 10-15, 2007; Moscow, Russia) who were eager to share some of the academic and clinical enthusiasm that defines the IMD meetings. The goal of the International Immune-Mediated Diseases: From Theory to Therapy (IMD) Congress is to bring the world’s best immunologists and clinicians to Moscow. |
| biologic therapies for severe asthma: Biologics, Biosimilars, and Biobetters Iqbal Ramzan, 2021-02-03 A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists |
| biologic therapies for severe asthma: Personalizing Asthma Management for the Clinician Stanley J. Szefler, Fernando Holguin, Michael E Wechsler, 2017-09-22 Personalized medicine is a rapidly emerging area in health care, and asthma management lends itself particularly well to this new development. This practical resource by Dr. Stanley J. Szefler helps you navigate the many asthma medication options available to your patients, as well as providing insights into those which may be introduced within the next several years. - Features a wealth of information on available asthma medications, including new immunomodulators, new responses to treatment, and new treatment strategies at all levels of asthma care. - Prepares you to meet your patients' needs regarding asthma exacerbation prevention and asthma prevention. - Consolidates today's available information and guidance in this timely area into one convenient resource. |
| biologic therapies for severe asthma: Asthma Adherence , 1999 |
| biologic therapies for severe asthma: Adverse Reactions to Biologics L. Puig, W. Gulliver, 2017-11-07 In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer. In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases. Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field. |
| biologic therapies for severe asthma: Asthma: Targeted Biological Therapies Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli, 2016-11-10 This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma. |
| biologic therapies for severe asthma: Allergy and Asthma , 2019-06-25 Allergy and Asthma: The Basics to Best Practices is intended to serve as a single comprehensive reference covering all needed knowledge of allergic diseases. Allergy is a unique and distinctive area of medicine wherein learning the fundamentals requires gathering information from various different disciplines. Allergic diseases affect various organ systems and the practice of a wide range of physicians from otolaryngologists, and pulmonologists, to gastroenterologists, dermatologists, and ophthalmologists. Clinicians and trainees alike will benefit from a resource that introduces the basic concepts, as well as providing comprehensive, consistently up-to-date instruction on intermediate and advanced conditions, research, and treatment strategies. The book is divided into nine sections and is written by some of the foremost experts in the field. Allergy and Asthma opens with an introduction which covers the epidemiology of allergic diseases, fundamentals of allergy and immunology, and a thorough grounding of different types of allergens. Early sections address allergic upper airway diseases, allergic skin diseases, and asthma in detail, using a structured, consistent format from chapter to chapter to provide continuity and ease of reference. Later sections thoroughly cover various food allergies, insect allergies, drug allergy, anaphylaxis, and utilize ample tables and illustrations to provide additional learning tools for the reader. This major reference not only provides basic knowledge on diagnosing and treating allergies, but moves beyond these basics to emphasize using a systematic approach to working up and treating a patient. A variety of techniques used in diagnosing asthma and allergy will be examined, of which include prick skin tests, in-vitro testing, patch testing and non-conventional allergy tests. Concluding this book are sections dedicated to management, therapeutic strategies of allergy and asthma, with a look to future research directions for this unique field. Physicians and residents in allergy and immunology, pulmonology, otolaryngology, gastroenterology, dermatology, ophthalmology and other specialties will find the work of value in enhancing their practice and studies. Researchers in a range of areas especially immunology and food science will also find this text to be a compelling and reliable resource. |
| biologic therapies for severe asthma: Eosinophils in Health and Disease James J. Lee, Helene F. Rosenberg, 2012-11-02 Eosinophils in Health and Disease provides immunology researchers and students with a comprehensive overview of current thought and cutting-edge eosinophil research, providing chapters on basic science, disease-specific issues, therapeutics, models for study and areas of emerging importance. |
| biologic therapies for severe asthma: Airway Remodeling Peter Howarth, John William Wilson, Jean Bousquet, Sabina Rak, Romain Pauwels, 2001 This landmark volume discusses the characteristics and impact of the remodeling process on airway function and clinical disease expression within the airway in asthma, covering pharmacological therapies and possible future targets relevant to regulating the remodeling process. Emphasizes the importance of treating underlying airway inflammation and the relevance of structural alterations to the airway wall, including glandular increases, enhanced collagen deposition within the submucosa, increased vasculature, smooth hypertrophy, and hyperplasias! Tracing the development and maintenance of bronchial hyperresponsiveness, decline in lung function, and loss of reversibility evident in chronic asthma, Airway Remodelingdescribes the contribution of inflammatory cells in the development of airway structural changes examines how pharmaceutical agents act and whether existing treatments modify or prevent remodeling in chronically inflamed asthmatic airways considers whether neural pathways initiate as well as contribute to the airway inflammatory cascade that leads to remodeling reviews the action of cytokines and growth factors on ASM signaling outlines novel approaches to regulating smooth muscle growth clarifies whether permanent ventilatory incapacity in asthma is caused by the uncoupling of the airway and the role of the lung parenchyma details high-resolution computerized tomography scan to measure the internal size of the airway at baseline, during challenge, or after bronchodilatation and more!Improving lung function and quality of life by reducing the need for emergency care, hospital admissions, and systemic steroid administration, Airway Remodeling is a superb reference for pulmonologists and respiratory system specialists; physiologists; pneumologists; allergists; pharmacologists; molecular, cellular, and lung biologists; and graduate and medical school students in these disciplines. |
| biologic therapies for severe asthma: Antibiotics as Anti-Inflammatory and Immunomodulatory Agents Bruce K. Rubin, Jun Tamaoki, 2005-02-14 Although the potential for immunomodulation has been recognized for many years there has been an explosion of data in this field with relevance especially to the treatment of chronic airway diseases. Most of the work in this field has been conducted by Japanese investigators but in the last decade there has been a body of work outside of Japan that supports and enhances these findings. The book covers basic research like effects on bacteria, anti-inflammatory and mucoregulatory effects, but also clinical results with up-to-date information for the use of such medications to potentially treat diseases as diverse as chronic airway diseases, arthritis, inflammatory bowel disease, and cancer. The volume is intended for pulmonary physicians, researchers in inflammation research, and pharmaceutical companies interested in the development of such agents. It provides background information for the clinician as well as in depth exploration of cutting edge science. |
| biologic therapies for severe asthma: Asthma Celso Pereira, 2019-10-02 Asthma is a prevalent disease in all age groups that results from different pathogenic mechanisms, cells, and mediators engaged in innumerous clinical phenotypes and endotypes. This book exhaustively and didactically explores the biological expression of numerous cells and mediators involved in bronchial inflammation. The information provided aims at identifying the diversity and complexity of the interrelationships between the different players, drawing attention to critical mechanisms in asthma. It also highlights the requirement of new tools to identify strong biomarkers absolutely critical for managing asthma. |
| biologic therapies for severe asthma: Cells of the Immune System Ota Fuchs, Seyyed Shamsadin Athari, 2020-05-13 The cells of the immune system are lymphocytes (T-cells, B-cells and NK (natural killer) cells), neutrophils, eosinophils, and monocytes/macrophages. This book is an overview of some types of these cells and their role in recognizing and/or reacting against foreign material. The immune system is characterized by collaboration between cells and proteins. The development of all cells of the immune system begins in the bone marrow with a hematopoietic stem cell. Two chapters deal with neutrophils, three chapters with T-cells, four chapters with eosinophils, and other chapters review the immunomodulation of macrophages, the role of transcription factor KLF4 in regulating plasticity of myeloid-derived suppressor cells, immune reconstitution after allogeneic hematopoietic stem cell transplantation, and role of sorption detoxification in the therapy of acute radiation sickness. |
| biologic therapies for severe asthma: MRI of the Lung Hans-Ulrich Kauczor, 2008-11-12 During the past decade significant developments have been achieved in the field of magnetic resonance imaging (MRI), enabling MRI to enter the clinical arena of chest imaging. Standard protocols can now be implemented on up-to-date scanners, allowing MRI to be used as a first-line imaging modality for various lung diseases, including cystic fibrosis, pulmonary hypertension and even lung cancer. The diagnostic benefits stem from the ability of MRI to visualize changes in lung structure while simultaneously imaging different aspects of lung function, such as perfusion, respiratory motion, ventilation and gas exchange. On this basis, novel quantitative surrogates for lung function can be obtained. This book provides a comprehensive overview of how to use MRI for imaging of lung disease. Special emphasis is placed on benign diseases requiring regular monitoring, given that it is patients with these diseases who derive the greatest benefit from the avoidance of ionizing radiation. |
| biologic therapies for severe asthma: The Asthmas Vibeke Backer, Peter G. Gibson, Ian D. Pavord, 2022-09-05 The field of asthma has expanded in the last decade with specific drugs targeting the disease mechanisms. This book is an updated treatise covering diagnoses, phenotypes and endotypes of asthma along with its management. It includes diagnostic work-up which is required prior to medical assistance and basic immunology assessment, illustrating the types, severity, number of exacerbations due to disease activity, allergy or infections. As the treatment selection has changed from one size fits all to precision-based medicine, it aims to refine asthma management with right medication usage, neither overuse nor underuse, and initiation of the new hospital administered biologic drugs. Key Features • Covers both respiratory physiology and airway inflammation • Highlights the use of biologic drugs • Discusses precision-based medicine • Explores the comorbidities through clinical cases |
| biologic therapies for severe asthma: British Guideline on the Management of Asthma , 2008 |
| biologic therapies for severe asthma: Bronchial Asthma M. Eric Gershwin, Timothy E. Albertson, 2001-04-15 They asked if the sneezles came after the wheezles, or if the first sneezle came first. It has been nearly 25 years since the first edition of this textbook was published. During that time, we have witnessed an enormous improvement in the understanding of the basic pathophysiology of asthma and, more importantly, better treatment options. However, and with regret, the incidence and prevalence of asthma during this 25 year period increased significantly. Recent studies from the NIH highlight this point and illustrate that despite improved care and diagnosis, mortality continues to rise. In fact, asthma remains the most common chronic childhood illness and is among the most common chronic adult diseases. Despite improved medications, increased awareness, and a better understanding of the pathophysiology of this disease, mortality and morbidity continue to rise. Both international and national consensus positions have been published that offer guidance on treatment approaches. The importance of the primary care physician and provider cannot be overestimated in the appropriate diagnosis and management of this disease. The management options in asthma are changing rapidly with the advent of new drugs and approaches. The recent introduction of the leukotriene inhibitors has added an entirely new class of anti-inflammatory agents in the treatment of asthma. The potential of even newer approaches, including cellular modulation of the asthma patient with specific anti-IgE antibodies, opens up exciting possible treatments. |
| biologic therapies for severe asthma: Tourism In India- Status, Challenges And Opportunities Prof. Manoj Srivastava , Dr. Sidharth Shankar Raju , Dr. Gaurav Bhattacharya, 2021-10-21 Dr. Manoj Srivastava is a PhD from Manipal University Jaipur.Over three decades of experience in Hospitality Industry & Academia, Food Production Research,resulting made9 culinary based Limca Book of World Records. For which he is honored with Honorius Causa form England. He join the Hospitality Industry in 1990 when he joined the Taj Group of Hotels. He rose quickly to product development and research. Joined Australian Bakels as National Support Manager. At Present associated as Professor& Principal,NIMS University, School of Hotel Management. He is authored a Book “The Art of research in Hospitality” and wrote many research papers in National and International journals of repute.He is on the board of many Journal as Editorial Board member & Reviewer of Hospitality & Tourism management journals. |
| biologic therapies for severe asthma: Childhood Asthma Stanley J Szefler, Soren Pedersen, 2005-09-26 This reference collects the latest studies on the development, diagnosis, and treatment of childhood asthma and offers current perspectives on new technologies that will shape the management of pediatric asthma in the forthcoming decade-illustrating how advances in pulmonary function measurement, inflammatory markers, imaging, and pharmacogenetics |
| biologic therapies for severe asthma: Middleton's Allergy E-Book A Wesley Burks, Robyn E. O'Hehir, David H. Broide, Stephen T Holgate, Leonard B. Bacharier, Gurjit K. Khurana Hershey, R. Stokes Peebles, 2019-09-25 Through eight outstanding editions, Middleton's Allergy: Principles and Practice has been the reference of choice for both clinicians and researchers as both a practical reference and an effective self-assessment tool for board preparation. The 9th Edition continues the tradition of excellence with comprehensive coverage of all basic science and clinical applications regarding allergy practice and disease mechanisms. It brings you fully up to date with recent innovations in the diagnosis, prevention, and management of allergic disorders, including emerging global issues, the advent of precision medicine, and new immunologic therapies. - Offers unparalleled depth and up-to-date guidance on the full spectrum of allergy across the lifespan, with significant updates throughout. - Contains new chapters on Innate Lymphoid Cells, Systems Biology, and Treatment of Primary Immunodeficiency Diseases. - Discusses emerging topics such as epidemic thunderstorm asthma and precision medicine in allergic disorders. - Features more than 730 full-color illustrations, including many new cellular and molecular drawings of disease mechanisms. - Includes new Summary of Important Concepts boxes, plus new multiple-choice questions online with explanations and answers. - Features a new team of expert editors and more international contributors for a global perspective of this complex field. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| biologic therapies for severe asthma: Antibody Fc Margaret Ackerman, Falk Nimmerjahn, 2013-08-06 Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance of the Fc domain, including protective mechanisms, effector cell types, genetic data, and variability in Fc domain function. This volume is a critical single-source reference for researchers in vaccine discovery, immunologists, microbiologists, oncologists and protein engineers as well as graduate students in immunology and vaccinology. Antibodies represent the correlate of protection for numerous vaccines and are the most rapidly growing class of drugs, with applications ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain, in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells. In addition, they provide a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. - Clarifies the different mechanisms of IgG activity at the level of the different model systems used, including human genetic, mouse, and in vitro - Covers the role of antibodies in cancer, infectious disease, and autoimmunity and in the setting of monoclonal antibody therapy as well as naturally raised antibodies - Color illustrations enhance explanations of the immune system |
| biologic therapies for severe asthma: Immunotherapy in Asthma Jean Bousquet, Hans Yssel, 1999-08-24 This massive reference thoroughly analyzes the mechanisms implicated in the pathophysiology of asthma, such as T helper lymphocyte subsets, and the consequences of various extrinsic and intrinsic factors, and IgE receptor expression-reviewing current concepts in immunotherapeutic approaches for the treatment of this and other allergic diseases. Investigates the only category of treatment showing the potential to affect the natural course of allergic diseases and prevent the onset of asthma. Written by more than 80 internationally renowned pulmonary experts, allergic disease specialists, and basic researchers, Immunotherapy in Asthma discusses the efficacy of new medications examines the role of metachromatic cells, lymphocytes, macrophages, and other cell types present in bronchial biopsies presents basic topics such as the functional and phenotypic properties of Th1 and Th2 cells and their role in allergic disease and the regulation of IgE-mediated inflammatory responses addresses the deleterious effects of smoking and passive exposure to cigarette smoke in children and adults assesses differences and similarities between intrinsic and antigen-induced asthma describes the effects of immunogenic peptides on the cytokine production profile of allergen-specific CD4+ T cells explains the different clinical aspects of allergic responses, such as bronchial hyperreactivity and eosinophilic inflammation of the airways reviews the genetic basis of allergy, as well as risk factors for asthma explores oral, sublingual, local nasal, and local bronchial routes for noninjective immunotherapies evaluates various agents with modulatory effects on normal and pathogenic immune responses focuses on strategies for the prevention of childhood asthma and more! Containing over 3000 references, drawings, and tables, Immunotherapy in Asthma is an indispensable resource for pulmonologists, immunologists, allergists, and medical school students in these disciplines. |
| biologic therapies for severe asthma: Biologic Therapies of Immunologic Diseases, An Issue of Immunology and Allergy Clinics of North America Bradley E. Chipps, Stephen P. Peters, 2017-04-12 This issue of Immunology and Allergy Clinics, guest edited by Drs. Bradley Chipps and Stephen Peters, is devoted to Biologic Therapies of Immunologic Diseases. Articles in this issue include: Immunologic Mechanisms and Potential Targets; Strategies for Immunologic Interventions; Patient Characteristics and Individualization of Therapy; Biologic Therapies for Autoimmune and Connective Tissue Diseases; Biologic Therapies for Skin Disease including Urticaria; Biologic Therapies for Asthma; Biologic Therapies for Rhinitis and Sinusitis; Biologic Therapies for Chronic Obstructive Pulmonary Disease; Biologic Therapies for Food Allergies and Eosinophilic Esophagitis; Future Prospects for Biologic Therapies of Immunologic Diseases; Pharmacoeconomics of Biologic Therapy; and Adverse Reaction to Biologic Therapy. |
| biologic therapies for severe asthma: Civetta, Taylor, & Kirby's Critical Care Andrea Gabrielli, A. Joseph Layon, Mihae Yu, Joseph M. Civetta, Robert Wesley Taylor, Robert R. Kirby, 2009 Now in its fourth edition, this leading critical care textbook contains more than 30 new chapters and completely updated information. The book addresses every problem encountered in the intensive care unit and covers surgical critical care more thoroughly than any other text. |
| biologic therapies for severe asthma: Human Eosinophils Gianni Marone, 2000 Eosinophils represent approximately 1% of peripheral blood leukocytes and play a central proinflammatory and immunoregulatory role in various immune disorders. This volume provides the reader with a comprehensive survey of the major aspects of human eosinophilic biology and immunology as well as the most clinically relevant aspects of eosinophil-related disorders. Expert contributions cover the ultrastructural and phenotypic characteristics of human eosinophils, and their fundamental biochemical features including receptors for IgE and chemokines. The production of cytokines and their role in the activation of eosinophils are reviewed. Furthermore, the classic eosinophil-related disorders such as hypereosinophilia, drug reactions, allergic disorders and some cardiovascular diseases are described. Each of the chapters is written by an investigator actively engaged in research on the topic under consideration. The well-edited and stimulating material compiled in this volume will be of interest to all those working in allergology, immunology, biochemistry and pulmonary medicine. |
| biologic therapies for severe asthma: Nocturnal Asthma Peter J. Barnes, Jonathan Levy, 1984 |
| biologic therapies for severe asthma: Pharmacotherapy of Asthma James Li, 2005-09-23 Standing as the only text focused on the pharmaceutical treatment of asthma, this reference details the pharmacology, mechanisms of action, efficacy, and safety of every drug currently used in the management and care of asthma patients. Internationally renowned authorities cover published practice guidelines, treatment plans, pharmacologic agents, and clinical studies to provide the most authoritative and up-to-date information on the use of medications to control and prevent this common condition. Reviewing the role of pharmacotherapy in the overall management of asthma, this guide: * reviews the pharmacology and clinical use of inhaled corticosteroids, beta adrenergic agonists, leukotriene modifiers, combination products, and many other asthma drugs * provides a practical framework for the optimal pharmacotherapy of asthma, focusing on outpatient therapy * examines international guidelines for the drug treatment of asthma. |
| biologic therapies for severe asthma: Newer Outpatient Therapies and Treatments, An Issue of Medical Clinics of North America Douglas Paauw, 2024-08-05 In this issue of Medical Clinics of North America, guest editor Dr. Douglas Paauw brings his considerable expertise to the topic of Newer Outpatient Therapies and Treatments. Top experts provide insights into recent pharmacologic treatments, review new uses for old drugs, discuss new technologies used in the outpatient setting, and address complementary/alternative options with strong evidence. - Contains 12 relevant, practice-oriented topics including therapy for hyperlipidemia; newer diabetes therapies and technologies; update on antiviral therapies; update in treatments for men's health; newer therapies for psychiatric disease; and more. - Provides in-depth clinical reviews on newer outpatient therapies and treatments, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| biologic therapies for severe asthma: Biologics for the Treatment of Allergic Diseases, An Issue of Immunology and Allergy Clinics of North America, E-Book Lanny J. Rosenwasser, 2020-10-15 This issue of Immunology and Allergy Clinics, guest edited by Dr. Lanny Rosenwasser, will provide up-to-date clinical concepts regarding Biologics for the Treatments of Allergic Conditions. Articles in this outstanding issue include: Allergic Rhinitis/CRS/Polyposis, Eosinophilic Asthma, Pediatric Asthma, Severe Asthma, ACOS/COPD, Food Allergy, Atopic Dermatitis, Chronic Urticaria, Anaphylaxis, Drug Allergy, Cell Disorders, Biologics and Immunotherapy, and much more. |
| biologic therapies for severe asthma: Clinical Updates in the Management of Severe Asthma Reynold A. Panettieri, Jr., MD, Michael E. Wechsler, MD, MMSc, 2018-02-23 This eHealth SourceTM program examines best practices for assessing disease control in patients with severe asthma, the evidence for current and emerging biologic medications, and strategies to improve patient education and treatment adherence. |
| biologic therapies for severe asthma: Clinical Aspects of Immunology D. K. Peters, P. J. Lachmann, M. J. Walport, 1992-12-31 |
| biologic therapies for severe asthma: Precision Approaches to Heterogeneity in Asthma Allan R. Brasier, Nizar N. Jarjour, 2023-07-18 Asthma is a common chronic respiratory disease that causes substantial morbidity and has been challenging to treat due to its heterogeneous onset, environmental triggers, severity, and treatment response. To update the field on the rapid advances in this field, Precision Approaches to Heterogeneity in Asthma follows its highly successful predecessor, Heterogeneity in Asthma. In this new volume, noted authorities Allan R Brasier and Nizar N Jarjour and a cadre of leaders in the field incorporate new work advancing our understanding of phenotypes (endotypes) of disease, regional variations in ventilation, systems approach to analyzing the findings from studies of inducible phenotypes, and emerging results of biomarker-informed clinical trials. This work will facilitate our current understanding of the spectrum of disease etiology, prognosis, and the likelihood of responding to the range of available therapeutic interventions. |
Electrochemical Instruments Manufacturer / BioLogic
Trusted for over 40 years by academic and industrial organizations worldwide, BioLogic measurement instruments, including potentiostats, battery cyclers, impedance analyzers, …
Products - BioLogic
BioLogic manufactures a variety of robust and user-friendly, potentiostats for diverse applications, from single-channel potentiostats to bipotentiostats to multichannel potentiostats.
Your new potentiostat: unboxing, setup and settings for your
Mar 28, 2022 · This short, easy-to-follow video series will show you exactly how quickly and easily you can set up your BioLogic potentiostat, using the example of the BioLogic SP-150e (the …
Discover Battery Cyclers - BioLogic
BioLogic ® offers a comprehensive line-up of battery cyclers, designed to support every stage of the battery development cycle through two complementary instrument ranges: Premium and …
What is Electrochemical Impedance Spectroscopy (EIS)? - BioLogic
May 23, 2025 · A leader in Electrochemical Impedance Spectroscopy (EIS) technologies, BioLogic strives to place EIS within every researcher's reach, by making it available on all of …
Battery Cycler brochure - BioLogic
May 19, 2025 · The MPG-200 series is a high-end battery testing system made up of two core configurations. The MPG-2 features 16 independent channels at 100 mA, whereas the MPG …
Discover Potentiostat / Galvanostat - BioLogic
BioLogic potentiostats/galvanostats are designed with modularity in mind, offering a wide range of configurations and optional add-ons and accessories that can be tailored to meet your specific …
Overview: Spectrometer solutions - BioLogic
Details of BioLogic's spectrometer solutions: circular dichroism, High throughput CD Microplate spectropolarimeters and pump-probe spectrometers
VSP-3e Potentiostat - BioLogic
Energy-specific functionality unique to BioLogic includes: Fast CCCV shift (constant current, constant voltage) Stack mode (follow individual elements in the pack) BCD (Battery capacity …
EC-Lab® OEM - BioLogic
This package offers an array of tools that enable seamless integration with proprietary software, giving users precise control over their BioLogic Potentiostat/Galvanostat instruments. Key …
Asthma and Biologics Report for the Rapid Uptake Group
3.0 DEFINITIONS OF DIFFICULT AND SEVERE ASTHMA AND BIOLOGIC THERAPIES Difficult and severe asthma 3.1 The definitions of severe and difficult asthma are challenging as asthma is a …
Choosing and Switching Biological Agents in Severe Asthma
Nov 8, 2022 · trial comparing different biologic therapies, initial and subsequent biologic choice usually relies on factors such as asthma phenotype, biomarker profile and need for OCS ...
Rapid Uptake Products Asthma Biologics AAC Consensus …
to be four times higher for uncontrolled severe asthma patients than for those with well-controlled asthma2. The advent of biologic therapies for severe asthma and the formalisation of specialised …
Clinical remission attainment, definitions, and correlates among ...
clinical remission with biologic therapies; 8–10. however, these studies have reported variable attainment due to differences in their populations, definitions, and methods. In this systematic …
Biologic Therapy and Novel Molecular Targets of Severe …
Treatment options for severe or unc ontrolled asthma a re increasing, especially pertaining to novel biologic therapies. The 2 primary asthma endotypes, T2 high and T2 low, are de fined by the …
Clinical remission with biologic therapies in severe asthma: …
We read with interest the editorial “Clinical remission with biologic therapies in severe asthma: a matter of definition” [1]. We absolutely agree that the definition of clinical remission is of critical …
Mucus Plugging as a Prognostic Indicator for Biologic …
Whereas the importance of mucus occlusions in asthma and fatal asthma has been well understood since the work 65 years ago by Dunnill,1 recent work and the increasing use of novel biologic …
An Update on Monoclonal Antibody Therapy to Treat Moderate …
therapies. These biologic therapies directly attack culprit inflammatory mediators at the molecular level. In this article we review currently available biologic agents for the treatment of moderate …
Comprehensive Evaluation of Biologic Therapies in Severe …
Comprehensive Evaluation of Biologic Therapies in Severe Asthma: A Meta-analysis on Exacerbation Reduction, Lung Function Improvement, ... and boosted quality of life for individuals with severe …
SEVERE ASTHMA - Health Innovation Oxford
Development of biologic therapies for treatment of severe asthma and the national requirement to establish severe asthma networks (“Severe Asthma Services in Adults” (commissioning …
Real-world comparative effectiveness of biologic therapies in …
Real-World Comparative Effectiveness of Biologic Therapies in Severe Asthma: EU-ADVANTAGE Giorgio Walter Canonica1, Johann Christian Virchow2, Arnaud Bourdin3, Juby Jacob-Nara4$, …
Mucus Plug Score Predicts Clinical and Pulmonary Function …
Jan 16, 2025 · biologic therapies. OBJECTIVES: To analyze associations of baseline characteristic with the mucus plugging score (MPS) and to determine whether the MPS at baseline predicts the …
Greater Exacerbation Reductions With Earlier Biologic Initiation …
RATIONALE: Biologic therapies are effective in reducing exacerbations in patients with severe asthma (SA). Few studies have examined whether effectiveness varies by how soon biologics are …
Biologic Therapies For Severe Asthma
Biologic Therapies For Severe Asthma biologic therapies for severe asthma: Severe Asthma Kian Fan Chung, Elliot Israel, Peter G. Gibson, 2019-06-01 Severe asthma is a form of asthma that …
The severe asthma pathway for NHS Highland*
• Patients with severe asthma should remain on regular maintenance ICS doses • Consider re-discussion at Severe Asthma MDT Poor response3 Assess treatment compliance • Reassess …
Severe asthma: oral corticosteroid alternatives and the need …
OCS-sparing effect of biologic therapies Several biologic therapies for the treatment of uncontrolled severe asthma are currently available. Omalizumab targets immunoglobulin E (IgE) …
How to adjust asthma management once asthma is controlled …
May 26, 2025 · 172 those patients with the most robust response to a biologic may be the most likely to fail when 173 Journal Pre-proofthe biologic is stopped. 174 175 Of the remaining biologic …
Biologic Therapies for Severe Asthma - med-space.ch
probably a larger proportion of cases of severe asthma are type 2–high asthma.8,9 This review outlines recent insights into type 2 inflammation in asthma and the currently available biologic …
Single cell RNA-seq discovery of blood biomarkers predicting …
Apr 16, 2025 · Biologic monoclonal antibody therapies for severe asthma23 target the Type 2 endotype through . 24. blockade of the IgE, IL -5/eosinophil, or IL -4/13 pathways, which …
Exploring Perceptions of Biologic Therapies: A Qualitative
how having severe asthma affects their lives, their current and previous asthma treatments, and their views on biologics. Ten people in this study were currently taking or had previously taken …
Severe asthma – A pragmatic guide for primary care …
access to biologic agents for patients with severe asthma as a key target for their Rapid Uptake of Products (RUP) programme. 4 AAC have worked with a number of organisations to develop tools …
Biologic Therapies for Severe Asthma - pure.eur.nl
Biologic Therapies for Severe Asthma entiation, activation, and survival of eosinophils. The numbers of eosinophils in peripheral blood, bronchoalveolar lavage fluid, and bronchial bi-opsy specimens …
Supratherapeutic Inhaled Corticosteroid Use in Patients …
of biologic therapies for severe asthma [6 ]. ICS is generally considered to have a at dose–response curve, with the principal therapeutic benets seen at low-to-moderate daily doses [–97]. …
REVIEWS Severe Asthma and Biologics: Managing Complex …
a major comorbidity of severe asthma. The definition of the phenotype/endotype of both asthma and CRSwNP is crucial, given the availability of novel biologic agents for patients who do not …
Biomarkers to predict response to biologic therapies and …
SEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1 1 Section 2: Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Biomarkers Study …
Longitudinal Assessment of Glucocorticoid Toxicity Reduction …
The International Severe Asthma Registry reported that 49% of their Global Initiative for Asthma (GINA) step 5 patients were receiving daily maintenance OCS (mOCS) as part of their usual …
Monoclonal antibody therapy for severe asthma - National …
Real-world observational studies have confirmed the effectiveness of all four monoclonal antibody therapies in patients with severe asthma treated in clinical practice.23 The body of real-world …
Changing Paradigms in the Treatment of Severe Asthma: The …
characteristics of severe asthma, asthma phenotypes in treatment selection, the role of T helper cell type 2 (Th2) pathways in severe asthma, and the efficacy, safety, and mechanisms of action of …
Biologic Therapies for Treatment of Moderate-to- Severe
Asthma Management with Biologic Therapies. Table 1: Monoclonal Antibody Therapies for Moderate-to-Severe Uncontrolled Asthma . Drug Dosing Mechanism FDA Indication Omalizumab …
HOW DO BIOLOGICS WORK FOR ASTHMA? MONOCLONAL
immunologist, allergist, or general physician experienced in the management of patients with severe asthma). Unless the diagnosis of severe asthma was made by a multidisciplinary severe asthma …
Advances in Asthma Management: Integrating Biologics, …
Recent Advancements in Biologic Therapies Biologics have transformed severe asthma management by targeting specific inflammatory mediators (Table 1). Table 1: Biologic Therapies …
Rapid Uptake Products Asthma Biologics AAC Consensus …
to be four times higher for uncontrolled severe asthma patients than for those with well-controlled asthma2. The advent of biologic therapies for severe asthma and the formalisation of specialised …
Real-World Biologic Use Patterns in Severe Asthma, …
Biologics are an effective add-on treatment in many patients with severe asthma and reduce exacerbations and the need for long-term OCS (LTOCS) while improving symptom control and …
Results from the nationwide Danish Severe Asthma Register …
111 INTRODUCTION 112 Severe asthma affects approximately 4-10% of the adult asthma population and despite being a 113 small proportion, these patients account for a disproportionate share of …
Clinical Remission in Severe Asthma: A Pooled Post Hoc
Feb 18, 2022 · The advent of biologic therapies in severe asthma has shed light on the utility of pheno-typing as a precision approach to treatment targeting key drivers of the disease …
Supratherapeutic Inhaled Corticosteroid Use in Patients …
to describe the prevalence of supratherapeutic ICS use in severe asthma, its relation to corticosteroid-related comorbidities, and changes in prescribed and redeemed ICS dose after 12 …
Efficacy of Biologics in Patients with Allergic Severe Asthma, …
The efficacy of biologic therapies by BEC in severe asthma has been previously systemati-cally summarized [20]; however, no such review has been conducted for patients with allergic severe …
Clinical Response and Remission in Patients With Severe …
BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal. RESEARCH QUESTION: …
Real-life small airway outcomes in severe asthma patients …
Feb 2, 2021 · patients with severe asthma receiving biologics. Impulse oscillometry (IOS) can be useful as an adjunct, particularly in those with baseline IOS-defined SAD. In Scotland, the …
The potential promise and challenge for tezepelumab as a …
biologic) with severe asthma, tezepelumab was comparable or better. Compared with omalizumab in patients with allergic asthma, results for tezepelumab were inconclusive regarding benefit in …
Clinical and economic burden of severe asthma among US …
severe asthma who are noneosinophilic without a highly effective biologic option if standard therapy fails to control their asthma.17,18 In addition, some patients with eosinophilic asthma respond …
Glucocorticoid Insensitivity in Severe Asthma: Underlying …
Biologic Therapies; Glucocorticoid Insensitivity; Glucocorticoid Receptor Signaling; Inflammation; Inhaled corticosteroids; Interleukins; Janus Kinase Inhibitors; NF-κB Activation; Severe Asthma. …
Safety of Biological Therapies for Severe Asthma: An …
The evaluation of severe asthma prevalence is still debated; in literature, the estimated frequency ranges from 1.8 to 38.9% among all asthma patients [, 23]. These values are aected by dierent …
Biologics in severe asthma: A pragmatic approach for …
May 10, 2023 · ing therapies than using subtypes based on inflammatory mechanisms, or endotypes. A paradigm of 2 endotypes, type 2 high and type 2 low, ... Currently approved …
Difficult-to-Treat and Severe Asthma: Management …
biologic add-on therapies, such as a long-acting muscarinic agent (LAMA) or leukotriene receptor antagonist, should ... Type 2 inflammation occurs in 50% of people with severe asthma and …
GINA DIFFICULT-TO-TREAT & SEVERE ASTHMA
Check local eligibility criteria for specific biologic therapies as these may vary from those listed. LABA: Long-acting beta2-agonist ... Severe asthma often interferes with family, social and …
Asthma Biologics
Asthma Bronchodilators Glucocorticoids Exacerbation KEY POINTS Asthma biologics are effective add-on therapies for severe, uncontrolled asthma and should be considered in patients who …
Systematic literature review of asthma biologic self …
Aug 28, 2024 · new add-on biologic therapies for severe asthma have been devel-oped2-8 and are associated with reduced exacerbation risk, improved asthma control, enhanced health-related …
REPORT AT A GLANCE: ASTHMA DECEMBER 2021 - ICER
patients with severe asthma, including in some types of asthma for which other biologic therapies are not effective. Because severe asthma is more prevalent among Black Americans, health gains …
Biologic Therapies for Treatment of Asthma Associated with …
Nov 13, 2018 · Severe asthma comprises a small but important subset of all individuals with asthma. Those with severe asthma represent fewer than 5-10% of all individuals with asthma but account …
